Phase I trial of the combination of the pan-ErbB inhibitor neratinib and mTOR inhibitor everolimus in advanced cancer patients with ErbB family gene alterations

ABSTRACT:

SUBMITTER: Piha-Paul S 

PROVIDER: S-EPMC11847258 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature